Revolution Medicines' GAAP loss for 3 months of 2022 was $57.647 million, up 55.1% from $37.176 million in the prior year. Revenue declined 25.2% to $7.578 million from $10.131 million a year earlier.

Revolution Medicines' GAAP loss for 2021 was $187.091 million, up 73% from $108.159 million the previous year. Revenue decreased 31.6% to $29.39 million from $42.983 million a year earlier.

Revolution Medicines' GAAP loss for 9M 2021 was $134.415 million, up 81.8% from $73.955 million in the prior year. Revenue decreased 41.8% to $19.93 million from $34.232 million a year earlier.

Revolution Medicines' GAAP loss for 6M 2021 was $81.475 million, up 74.3% from $46.734 million in the previous year. Revenue decreased 12.7% to $18.829 million from $21.571 million a year earlier.